Pfizer, Bluebird Bio, Inhibrx, and more!

Welcome back everybody, to another edition of “BioPharma Bitez,” the top news in the industry as well as one story outside of it. And outside of it this week, our next vacation could be in space, so, stick around to learn more.

So, to kick things off this week, Pzifer is in hot water with the media this week, for releasing data that shows Enbrel might be a potential Alzheimer’s preventative therapy this week and chose not to research it. So, this is some much older data. They did do some internal screening but saw no potential in profiting it, so, they decided to scrap any plans of doing that. So, we are waiting to see what comes of that.

Bluebird Bio has got EU approval for its gene therapy product Zynteglo, which is actually for beta-thalassemia patients, and it is a curative therapy so no price tag yet. We’re expected to get that in the next week or so, so based on how expensive Novartis was last week; it could be in the millions of dollars again. We will see.

Celgene has a partner named Inhibrx, which is looking to have a 75 million dollar IPO this week for its oncology pipeline, which is a very exciting time for them.

The Trump Administration has announced this week they are cutting funding to fetal tissue research, which is commonly used for many cell therapies as well as for HIV therapy research.

La Jolla Pharmaceuticals this week has released positive phase-two data for its lead product for hemochromatosis which is heavy excess iron buildup in the bloodstream. It would be the first new product in many years for patients suffering from that, and they did show a forty-two percent reduction in one of the key endpoints for that study. So, positive data there, great to hear that.

Now kicking it out to potential space vacations, NASA has announced this week starting in 2020 they’ll start allowing private ventures up to the space station. Starting with companies renting it out for short periods and then potentially moving it towards civilian check-out use for basically fancy Airbnb. So, we can’t wait to see what actually comes of that as NASA continues to expand different ways of raising monetary funds for its future endeavors.

Now, kicking it to my side of the business this week, I am still working on that executive director of RA strategy role. Anyone in RA strategy, especially global strategy I’m encouraging you to reach out to me and learn more about it. As well, I am still working on quite a few quality roles, including QC analytical development. So, anyone in manufacturing, analytical development, quality, or for regulatory affairs, please feel free to reach out and share this among the network that you have. I thank you all for tuning in, and I will see you all next week for another edition of “BioPharma Bitez.”